


**Patient characteristics** of women undergoing MVA in the during the RCT in Western Kenya between May 2022 and September 2023

| Characteristics      | Spinal Needle<br>(n = 105) | Syringe Extender<br>(n=105) | Total (n = 210) |
|----------------------|----------------------------|-----------------------------|-----------------|
| Age yrs median (IQR) | 27 (22,31)                 | 28 (22,32)                  | 26 (22,32)      |
| Parity               |                            |                             |                 |
| Nulliparous n (%)    | 35 (33.3)                  | 29 (27.6)                   | 64 (30.5)       |
| Parous n (%)         | 68 (64.8)                  | 76 (72.4)                   | 144 (68.6)      |
| Education n (%)      |                            |                             |                 |
| None                 | 1 (1.0)                    | 2 (1.9)                     | 3 (1.4)         |
| Primary School       | 17 (16.2)                  | 13 (12.4)                   | 30 (14.3)       |
| Secondary School     | 48 (45.7)                  | 56 (53.3)                   | 104 (49.5)      |
| University           | 37 (35.2)                  | 34 (32.4)                   | 71 (33.8)       |
| Mean Gest age n (SD) | 9.4 (2.1)                  | 9.6 (2.7)                   | 9.6 (2.4)       |

IQR Interquartile range

**Consort flow diagram** of study participants in the SED RCT done in Western Kenya amongst women undergoing MVA May 2022 – Sept 2023



**Adverse events** – There were no adverse events during the study

**Primary and Secondary Outcomes** (Intention-to-Treat Analysis). Pain scores at different time points segregated by study arm for women undergoing MVA in the syringe extender RCT in Western Kenya between May 2022 and September 2023

| Time points          | Spinal Needle<br>(n = 105) | Syringe<br>Extender<br>(n=105) | Difference of<br>Means (90%<br>CI) |
|----------------------|----------------------------|--------------------------------|------------------------------------|
| Before MVA           | 3.5 (3.2 -3.8)             | 3.7 (3.3 – 4.1)                | 0.2 (-0.3 – 0.7)                   |
| Speculum Insertion   | 3.8 (3.4 – 4.2)            | 4.5 (4.1 – 5.0)                | 0.7 (0.2 – 1.2)                    |
| PCB Injection        | 5.0 (4.6 - 5.4)            | 5.4 (5.0-5.7)                  | 0.4 (-0.1-0.9)                     |
| Uterine Evacuation*  | 3.6 (3.2-4.1)              | 4.0 (3.5-4.4)                  | 0.3 (-0.2-0.9)                     |
| 30 minutes after MVA | 2.6 (2.2-2.9)              | 2.7 (2.3-3.1)                  | 0.1 (-0.4-0.6)                     |

Data are mean pain scores (90% confidence interval) on an 11-point NRS. \* Primary outcome

**Difference in Mean Pain Scores** in Relation to Non-inferiority Limit (Intention-to-Treat Analysis) comparing the experimental SED to spinal needle for PCB amongst women undergoing MVA in Western Kenya (May 2022 – Sept 2023)

